ValuEngine Lowers Tetraphase Pharmaceuticals (TTPH) to Strong Sell
Tetraphase Pharmaceuticals (NASDAQ:TTPH) was downgraded by research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.
A number of other equities research analysts have also issued reports on TTPH. Zacks Investment Research raised Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 target price on the stock in a research report on Wednesday, August 9th. BidaskClub lowered Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Piper Jaffray Companies started coverage on Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They set an “overweight” rating and a $14.00 target price on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price target on shares of Tetraphase Pharmaceuticals in a report on Tuesday, September 12th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $15.15.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down $0.11 during trading on Friday, hitting $6.31. The stock had a trading volume of 501,239 shares, compared to its average volume of 710,883. Tetraphase Pharmaceuticals has a 12 month low of $3.57 and a 12 month high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.63). The company had revenue of $4.10 million for the quarter, compared to analyst estimates of $1.59 million. Tetraphase Pharmaceuticals had a negative return on equity of 88.27% and a negative net margin of 1,382.33%. Tetraphase Pharmaceuticals’s revenue for the quarter was up 355.6% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.58) earnings per share. research analysts anticipate that Tetraphase Pharmaceuticals will post -2.88 EPS for the current fiscal year.
In other news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction on Tuesday, October 31st. The stock was sold at an average price of $6.03, for a total transaction of $52,762.50. Following the transaction, the insider now owns 8,750 shares in the company, valued at $52,762.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 5.50% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. UBS Group AG grew its holdings in shares of Tetraphase Pharmaceuticals by 2.3% during the first quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock valued at $159,000 after buying an additional 387 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Tetraphase Pharmaceuticals by 0.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 874 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Tetraphase Pharmaceuticals by 5.7% during the second quarter. Rhumbline Advisers now owns 51,633 shares of the biopharmaceutical company’s stock valued at $368,000 after buying an additional 2,780 shares in the last quarter. Voya Investment Management LLC grew its holdings in shares of Tetraphase Pharmaceuticals by 17.8% during the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 3,104 shares in the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of Tetraphase Pharmaceuticals by 6.9% during the second quarter. Alliancebernstein L.P. now owns 59,200 shares of the biopharmaceutical company’s stock valued at $422,000 after buying an additional 3,800 shares in the last quarter. Institutional investors and hedge funds own 58.25% of the company’s stock.
WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/valuengine-lowers-tetraphase-pharmaceuticals-ttph-to-strong-sell/1738064.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.